Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Seer, Inc., a Nasdaq-listed company specializing in deep proteomic insights, has filed a patent infringement lawsuit against Nanomics Biotechnology, asserting that Nanomics' products infringe on several of Seer's U.S. patents related to nanoparticle protein enrichment. The company emphasizes the strength and robustness of its intellectual property …
Colliers International Group Inc. has initiated a new normal course issuer bid (NCIB) enabling the company to repurchase up to 4.3 million subordinate voting shares, approximately 10% of its public float, from May 2026 to May 2027. This move reflects Colliers’ confidence in its share value and commitment to enhancing shareholder value. All repurcha…
Upstream Bio reported first quarter 2026 financial results and significant progress in its clinical development programs targeting severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and chronic obstructive pulmonary disease (COPD) with its investigational drug verekitug. The company plans Phase 3 trial initiations for severe asthma a…
Lightbridge Corporation and Studsvik Scandpower have formed a partnership to develop an advanced software extension for modeling Lightbridge's next-generation metallic nuclear fuel design. This collaboration aims to support the licensing and commercial deployment of Lightbridge Fuel in light water reactors, promising improvements in safety, economi…
CTW reported a 1% decline in revenue to $40.9 million for the first half of fiscal 2026 compared to the prior year period. Despite modest revenue softness due to underperformance of new game launches and lifecycle trends in legacy titles, the company achieved a 55% increase in segment profit and 16% rise in Adjusted EBITDA by optimizing marketing s…
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company focused on developing novel FASN inhibitors for metabolic and fibrotic diseases, announced its participation in the H.C. Wainwright 4th Annual BioConnect Investor Conference with a fireside chat scheduled on May 19, 2026. The event will be webcast and archived for investors and me…
OIO Group announced it has entered into a term sheet for the proposed acquisition of a privately held German automotive engineering and low-volume production platform. The acquisition aims to strengthen OIO's engineering depth, prototype capability, and operational infrastructure in Europe, supporting the ongoing development and production of the D…
Can-Fite BioPharma Ltd. announced advancement of its pancreatic cancer drug Namodenoson into a Phase 2b study combining it with immunotherapy. This follows encouraging Phase 2a data showing favorable safety and clinical activity in advanced pancreatic adenocarcinoma patients. The company plans to discuss study design and partnership negotiations at…
Corbus Pharmaceuticals Holdings, a clinical-stage biotech company focusing on oncology and obesity therapies, disclosed that CEO Yuval Cohen will present at both the RBC Capital Markets and Jefferies Global Healthcare Conferences in May and June 2026, respectively. These presentations aim to update investors on company progress, including their pip…
Victoria’s Secret & Co. invites investors and analysts to listen to its Q1 2026 earnings webcast on June 2 at 8:30 a.m. ET, with the related financial release anticipated approximately one hour prior. The company operates globally with leading brands including Victoria’s Secret, PINK, and Adore Me, and provides a detailed safe harbor statement high…
Nurix Therapeutics, a clinical-stage biopharmaceutical company specializing in targeted protein degradation therapies, announced that CEO Arthur T. Sands will participate in fireside chats at the RBC Global Healthcare Conference and the Jefferies Global Healthcare Conference in May and June 2026. These events are opportunities for Nurix to present …
Humacyte, Inc. (Nasdaq: HUMA) announced its first quarter 2026 financial results, highlighting increased sales of its vascular graft product Symvess, key strategic hires in commercial and surgical leadership, acceptance of its marketing application in Israel, a new purchase commitment in Saudi Arabia, and upcoming top-line interim Phase 3 trial res…
Opus Genetics, a clinical-stage biopharmaceutical company specializing in gene therapies for inherited retinal diseases, announced its management will present at the RBC Capital Markets 2026 Global Healthcare Conference on May 19, 2026. The company focuses on developing one-time gene therapy treatments addressing genetic causes of severe retinal di…
BioCryst Pharmaceuticals announced new real-world data presentations at ISPOR 2026 highlighting the significant healthcare resource utilization and quality-of-life impact of hereditary angioedema (HAE) on pediatric patients and their caregivers. The studies underscore ongoing unmet needs and the importance of optimized disease management in this ra…
Kornit Digital Ltd. announced its Q1 2026 results with revenues of $48.5 million at the top end of guidance, a 103% increase in All-Inclusive Click (AIC) revenues year-over-year, and positive operating cash flow for the tenth consecutive quarter. The company highlighted strong traction in digital fashion and textile production driven by product inn…
Beam Therapeutics announced its CEO, John Evans, will present at the 2026 RBC Capital Markets Global Healthcare Conference. The presentation will highlight Beam's advancements in precision genetic medicines using their proprietary base editing technology. The conference presentation will be webcast live and archived for investor access.
PDS Biotechnology Corporation announced its first quarter 2026 financial results and clinical updates, highlighting progress in its immunotherapy clinical trials including amendments to the VERSATILE-003 Phase 3 trial for HPV16-positive head and neck cancer and positive biomarker data from metastatic colorectal cancer and prostate cancer trials. Th…
RTB Digital, Inc. announced the closing of its merger with RYVYL Inc. and the commencement of trading on the Nasdaq Capital Market under the ticker RTB. The company offers a pioneering AI, DeFi, and Web3 enabled enterprise media platform designed to transform the global premium media industry by integrating decentralized publishing, data protection…
Tower Semiconductor announced its first quarter 2026 financial results showing a 15% year-over-year increase in revenue to $414 million, along with significant growth in gross profit and operating profit. The company projects record revenue of $455 million for Q2 2026, driven by robust demand and strategic advances, particularly in silicon photonic…
Kamada Ltd. reported Q1 2026 revenues of $45.2 million, a 3% year-over-year increase, with adjusted EBITDA of $11.6 million and net income rising 4% to $4.1 million. Despite a temporary shipment delay, demand for key products like KEDRAB in the U.S. and KAMRAB and VARIZIG in international markets is rising. The company reaffirms its 2026 revenue gu…
Atea Pharmaceuticals announced that three abstracts highlighting their progress in oral antiviral treatments for viral hepatitis have been accepted for presentation at the EASL Congress 2026. The presentations feature clinical and preclinical data on their hepatitis C fixed-dose combination regimen (bemnifosbuvir and ruzasvir) showing promise in Ph…
HUYA is trading below $3.25 despite a resilient business mix, growing engagement signals and a rising short interest that now looks crowded. With a $697M market cap, a demonstrable pattern of shareholder distributions and improving technical momentum, HUYA offers asymmetric upside into $4+ while keeping a tight stop below $2.60. This is a mid-term …
A report that Health Minister Wes Streeting is preparing to resign as early as Thursday to force a leadership contest has diverted attention from the King’s Speech, prompting a fall in long-dated government bond futures and raising the prospect of a deeper crisis within the Labour Party. Prime Minister Keir Starmer has so far downplayed internal ch…
In a programme of 37 bills presented as the government’s priorities for the coming parliamentary session, ministers have set out measures spanning trade, regulation, national security, immigration, energy and constitutional reform. The King’s Speech - delivered by the monarch but drafted by government ministers - follows internal pressure on Prime …
Prime Minister Keir Starmer said the government will introduce a European Partnership Bill to put in place agreements with the European Union now and going forward. The move, announced in the King's Speech, seeks to rebuild economic ties with the bloc while the prime minister faces calls to step down following electoral setbacks. The bill would ena…
